Tuesday, October 11, 2016

News: Spineology Interbody Devices Now FDA Approved with Allograft Bone

ecent approval facilitates healing time and reduces costs by pairing Musculoskeletal Transplant Foundation allografts with Rampart Interbody Fusion Devices

MINNEAPOLIS & ST. PAUL, Minn.--()--Spineology Inc. announced today that it has obtained FDA clearance for the use of allograft bone with its Rampart™ Interbody Fusion Devices.
“This approval and our recent partnership expansion with Musculoskeletal Transplant Foundation (MTF) provides us the ability to pair MTF allografts with the Rampart family of interbody devices”
Tweet this
“This approval and our recent partnership expansion with Musculoskeletal Transplant Foundation (MTF) provides us the ability to pair MTF allografts with the Rampart family of interbody devices,” says John Booth, CEO of Spineology. “In addition to reducing patient morbidity and enhancing surgical efficiency we expect this approval will provide Spineology with an excellent platform for delivery of our new Incite™ Cortical Fibers.”
Incite Cortical Fibers are a unique and versatile bone grafting solution. The fibers offer an osteoconductive and inductive matrix, excellent handling properties, in-situ expansion and placement options via a variety of delivery methods.
The Rampart Interbody fusion devices incorporate large graft windows to facilitate healing and a recently enhanced instrumentation system. Additionally, devices are now available sterile packed, eliminating the need for continual reprocessing, which reduces costs for our customers.
About Spineology Inc.
Spineology LogoSpineology Inc. provides innovative, anatomy conserving spinal technologies for surgeons and their patients. Spineology surgical techniques conserve spinal bone, ligament and muscle tissue. Spineology is committed to increasing procedural efficiency, reducing surgical morbidity and accelerating patient recovery. Learn more at spineology.com.

Contacts

Spineology Inc.
John Booth, 651-256-8511
or
Risdall Public Relations
Dave Folkens, 651-286-6713

Published at BusinessWire

No comments:

Post a Comment